New drug combo aims to keep relapsed blood cancer at bay
NCT ID NCT03622775
Summary
This study tested whether a combination of two drugs (daratumumab and pomalidomide) given as long-term maintenance therapy could help control multiple myeloma that returned after a stem cell transplant. The treatment was given for up to 3 years to 13 patients to see if it could achieve deep remission and delay cancer progression. The trial was terminated early, so results are limited.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.